They might look to buy a front-end marketing company in Europe or US to extend their portfolio in a new therapeutic area. MS has already mentioned backward integration to API purely for captive usage. Acquisition of Teva and scaling up on that will also consume some cash.
MS looks prudent in giving guidance. Let’s wait for their Q3’22 results.
| Subscribe To Our Free Newsletter |
